Most Read Articles
02 Apr 2019
Using preventive zinc and micronutrient powder supplementation does not appear to improve growth in children, a recent study has found.
Audrey Abella, 14 Oct 2020
Findings from the phase IIa T1GER study revealed the therapeutic potential of the monoclonal antibody golimumab for children and young adults with type 1 diabetes (T1D).

Systemic JIA: Tapering canakinumab feasible in children in complete remission

03 Sep 2020

For paediatric patients who achieved complete remission (CR) on canakinumab, it is possible to maintain this response while reducing exposure to the drug, as shown in a study.

However, only a few patients could discontinue canakinumab and remain in CR for at least 24 weeks, suggesting that a certain level of IL-1 inhibition may be essential to maintain CR.

The study was conducted in two phases. In the first phase, 182 patients received 4 mg/kg canakinumab subcutaneously every 4 weeks (q4w) and discontinued glucocorticoids and/or methotrexate as appropriate.

Seventy-five of the patients who achieved CR (inactive disease for 24 weeks) entered the second phase and were randomly assigned to two groups evaluating canakinumab tapering: arm 1 (dose reduction from 4 to 2 to 1 mg/kg and then discontinuation; n=38) or arm 2 (dose interval prolongation from q4w to q8w to q12w and then discontinuation; n=37).

CR persisted in most patients in arm 1 (71 percent) and in arm 2 (84 percent). These numbers were significantly higher when compared to the proportion of patients who were on CR for 24 weeks in the first study phase (vs 40 percent; p≤0.0001 for each arm).

However, in the combined arms, only 33 percent patients were able to discontinue canakinumab and remain in CR for at least 24 weeks.

There were no new safety signals identified.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Apr 2019
Using preventive zinc and micronutrient powder supplementation does not appear to improve growth in children, a recent study has found.
Audrey Abella, 14 Oct 2020
Findings from the phase IIa T1GER study revealed the therapeutic potential of the monoclonal antibody golimumab for children and young adults with type 1 diabetes (T1D).